Current Funding Opportunities
- External Funding
- Internal Grant Opportunities
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).
The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards
Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Fast Funding for COVID-19 Science
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.
Deadline: Fast Grant decisions are made in under 48 hours. Apply Now!
The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. Pre-application and application deadlines will be available when the Program Announcements are released.Learn more about the DoD Lung Award>>
DoD Peer Reviewed Cancer Research Program Funding Opportunities
The FY20 Defense Appropriations Act provides funding to the DoD Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.
- Virtual Cancer Center Director Award – Letter of Intent due July 30, 2020
- Career Development Award – Fellow Option – Letter of Intent due July 30, 2020
- Career Development Award – Cancer Center Scholar Option – Letter of Intent due July 30, 2020
- Behavioral Health Science Award – Letter of Intent due July 30, 2020
- Translational Team Science Award – Letter of Intent due July 30, 2020
Damon Runyon Fellows are eligible to apply in the fourth year of their Fellowship. This FO enables them to complete their training under the mentorship of a leading senior scientist and encourages them to follow their own bold ideas.
Application Deadline: July 15, 2020
Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43)
The purpose of this FOA is to establish an institutional program for mentored training in global cancer research.
This award is designed to enable innovative approaches to solving high-impact problems in cancer research that tend to fall outside the scope of other funding opportunities.
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and AYA Cancer Survivors (R01 and R21)
Through this FOA the NCI invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult cancer survivors.
Application Deadline: July 31, 2020
Application Deadline: August 12, 2020
Application Deadline: August 28, 2020
DoD Prostate Cancer Research Program Funding Opportunities for Fiscal Year 2020 (FY20)
The FY20 Defense Appropriations Act provides funding to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease.
3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2)
Through this FOA, the NCI, as a part of its Beau Biden Cancer Moonshot Initiative, invites submission of applications requesting support for projects that will accelerate cancer research.
Application Deadline: November 9, 2020
Alex's Lemonade Stand RUNX1 Early Career Investigator Grant
This grant is a 3-year award designed to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1-FDP.
Application Deadline: December 16, 2020